Ann Rheum Dis 2000;59:468-477 ( June )

Extended report

Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial C H M van Jaarsveld^a, J W G Jacobs^a, M J van der Veen^b, A A M Blaauw^a, A A Kruize^a, D M Hofman^{a c}, H L M Brus^c, G A van Albada-Kuipers^d, A H M Heurkens^d, E J ter Borg^e, H C M Haanen^e, C van Booma-Frankfort^f, Y Schenk^f, J W J Bijlsma^a, on behalf of the Rheumatic Research Foundation Utrecht, The Netherlands

^a Department of Rheumatology and Clinical Immunology, University Medical Centre, PO Box 85500, 3508 GA Utrecht, The Netherlands, ^b Department of Rheumatology, Hospital Sint Jansdal, PO Box 138, 3840 AC Harderwijk, The Netherlands, ^c Department of Rheumatology, Hospital Hilversum, PO Box 10016, 1201 DA Hilversum, The Netherlands, ^d Department of Rheumatology, Eemland Hospital, PO Box 1502, 3800 MB Amersfoort, The Netherlands, ^e Department of Rheumatology, Sint Antonius Hospital, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands, ^f Department of Rheumatology, Diakonessen Hospital, Bosboomstraat 1, 3582 KE Utrecht, The Netherlands

Correspondence to: Dr Jacobs Email: J.W.J.Bijlsma{at}DIGD.AZU.NL

Accepted for publication 12 January 2000

OBJECTIVESTo compare three therapeutic strategies using slow acting antirheumatic drugs (SAARDs) in early rheumatoid arthritis (RA), for their disease modifying properties, toxicity, and lag time until treatment effect.
METHODSPatients with recent onset RA from six hospitals were randomly assigned to immediate initiation of one of three treatment strategies: (I) a "mild SAARD with a long lag time" (hydroxychloroquine, if necessary replaced by auranofin); (II) a "potent SAARD with a long lag time" (intramuscular gold, if necessary replaced by D-penicillamine); (III) a "potent SAARD with a short lag time" (methotrexate, if necessary replaced by sulfasalazine). Comparisons included two years of follow up.
RESULTSAll SAARD strategies reduced mean disease activity. A greater percentage of patients improved clinically with strategies II and III than with strategy I: percentages of patients improved on joint score with strategies II and III (79% and 82%, respectively), which was statistically different from strategy I (66%). The same was true for remission percentages: 31% and 24% v 16%, respectively). Longitudinal analysis showed significantly less disability with strategy III, and a lower erythrocyte sedimentation rate with strategy II than with strategy I. In addition, radiological damage after one and two years, was significantly lower in strategies II and III (at two years median scores were 11 and 10 v 14 in strategy I, p<0.05). Toxicity was increased in strategy II compared with the other strategies.
CONCLUSIONStrategy III, comprising methotrexate or sulfasalazine, produced the best results weighing effectiveness and toxicity. Strategy I (hydroxychloroquine or auranofin) was slightly less effective, and strategy II (intramuscular gold or D-penicillamine) was associated with increased toxicity.

---

© 2000 by Annals of the Rheumatic Diseases
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Verstappen, S M M, Jacobs, J W G, van der Veen, M J, Heurkens, A H M, Schenk, Y, ter Borg, E J, Blaauw, A A M, Bijlsma, J W J, on the behalf of the Utrecht Rheumatoid Arthritis, (2007). Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 66: 1443-1449 [Abstract] [Full Text]  
• Baron, G., Boutron, I., Giraudeau, B., Ravaud, P. (2007). Reporting of radiographic methods in randomised controlled trials assessing structural outcomes in rheumatoid arthritis. Ann Rheum Dis 66: 651-657 [Abstract] [Full Text]  
• Verstappen, S M M, Hoes, J N, ter Borg, E J, Bijlsma, J W J, Blaauw, A A M, van Albada-Kuipers, G A, van Booma-Frankfort, C, Jacobs, J W G, on behalf of the Utrecht Rheumatoid Arthritis Coho, (2006). Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: the effect of treatment strategy. Ann Rheum Dis 65: 1506-1511 [Abstract] [Full Text]  
• Verstappen, S. M. M., Boonen, A., Bijlsma, J. W. J., Buskens, E., Verkleij, H., Schenk, Y., van Albada-Kuipers, G. A., Hofman, D. M., Jacobson, J. W. G., on behalf of the Utrecht Rheumatoid Arthritis Coho, (2005). Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions. Rheumatology (Oxford) 44: 202-206 [Abstract] [Full Text]  
• Verstappen, S M M, van Albada-Kuipers, G A, Bijlsma, J W J, Blaauw, A A M, Schenk, Y, Haanen, H C M, Jacobs, J W G, on behalf of the Utrecht Rheumatoid Arthritis Coho, (2005). A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 64: 38-43 [Abstract] [Full Text]  
• Verstappen, S M M, Verkleij, H, Bijlsma, J W J, Buskens, E, Kruize, A A, Heurkens, A H M, van der Veen, M J, Jacobs, J W G (2004). Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 63: 817-824 [Abstract] [Full Text]  
• Aletaha, D, Eberl, G, Nell, V P K, Machold, K P, Smolen, J S (2002). Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis 61: 630-634 [Abstract] [Full Text]  
• Hood, C, Johnson, J, Kelly, C (2001). What is the prevalence of rheumatic disorders in general medical inpatients?. Postgrad. Med. J. 77: 774-777 [Abstract] [Full Text]  
• Quinn, M. A., Conaghan, P. G., Emery, P. (2001). The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?. Rheumatology (Oxford) 40: 1211-1220 [Abstract] [Full Text]  
• Jansen, L M A, van der Horst-Bruinsma, I E, van Schaardenburg, D, Bezemer, P D, Dijkmans, B A C (2001). Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 60: 924-927 [Abstract] [Full Text]  
• Rozenfeld, V., Chagan, L., Kleyman, E. (2001). The Year in Review: Rheumatology. Journal of Pharmacy Practice 14: 54-69 [Abstract]